LOS ANGELES, Nov. 14, 2025 (GLOBE NEWSWIRE) — XMax Inc. (“Xmax” or the “Company”) (NASDAQ: XWIN), today announced its unaudited financial results for the three months ended September 30, 2025. Operating Results for the Three Months ended September 30, 2025Net Sales grew by 273% to $9.76 million from $2.62 million in the same period of 2024. Gross profit was $0.98 million, compared to $1.18 million in the same period of 2024. Net loss was $1.13 million, compared to a net loss of $2.47 million in the same period of 2024.Operating Results for the Nine Months Ended September 30, 2025:Net Sales grew by 95% to $14.95 million from $7.68 million in the same period of 2024. Gross profit was $3.47 million, compared to $3.39 million in the same period of 2024. Net loss was $1.76 million, compared to a net loss...

MIRAMAR, Fla., Nov. 14, 2025 (GLOBE NEWSWIRE) — HCW Biologics Inc. (the “Company” or “HCW Biologics”) (NASDAQ: HCWB), a clinical-stage biopharmaceutical company focused on discovering and developing novel immunotherapies to lengthen healthspan by disrupting the link between inflammation and diseases, today reported financial results and recent business highlights for its third quarter ended September 30, 2025. The Company anticipates dosing the first patient in a Phase 1 clinical study (NCT07049328) to evaluate HCW9302 in patients with an autoimmune disease in the fourth quarter of 2025. HCW9302 is the Company’s lead product candidate for its clinical program to develop treatments for autoimmune diseases and inflammatory conditions. HCW9302 is a subcutaneously injectable, first-in-kind interleukin 2 (“IL-2”) fusion molecule constructed...

HONG KONG, Nov. 14, 2025 (GLOBE NEWSWIRE) — Oriental Culture Holding LTD. (“OCG” or the “Company”) (NASDAQ: OCG), an online provider of collectibles and artwork e-commerce services, today announced its unaudited financial results for the six months ended June 30, 2025. First Half Year of 2025 Financial HighlightsTotal revenues were approximately $0.1 million for the six months ended June 30, 2025, compared with the total revenues of approximately $0.4 million for the six months ended June 30, 2024.Gross profit was approximately $0.1 million for the six months ended June 30, 2025, compared with approximately gross profit of $0.3 million for the six months ended June 30, 2024.Gross margin was 84.7% for the six months ended June 30, 2025, compared with a gross margin of 65.8% for the six months ended June 30, 2024.Loss from...

Revenue of $2.8 Million for Q3 2025, up 163% from Q3 2024 Gross Profit of $2.3 Million for Q3 2025, a 213% increase from Q3 2024; Gross Margin Expanded to 81.7% in Q3 2025, a 1,302 BPS Increase Management to Host Third Quarter 2025 Results Conference Call Today, Friday, November 14, 2025 at 4:30 p.m. Eastern Time SEATTLE, Nov. 14, 2025 (GLOBE NEWSWIRE) — Banzai International, Inc. (NASDAQ: BNZI) (“Banzai” or the “Company”), a leading marketing technology company that provides essential marketing and sales solutions, today reported financial results for the third quarter ended September 30, 2025. Third Quarter 2025 and Subsequent Key Financial & Operational HighlightsRevenue of $2.8 million for Q3 2025, representing an increase of 163% over Q3 2024. Gross profit of $2.3 million for Q3 2025, representing an increase of 213%...

FDA Agreement on BMD as Primary Endpoint for EB613 Registrational, Phase 3 Study EB613 Phase 2 Data Demonstrating Consistent Efficacy across Younger Post-Menopausal Women with Osteoporosis and its Impact on Trabecular and Cortical Bone Indices, Highlighted at NAMS and ASBMR Next-Generation EB613 Remains on Track for Phase 1 Initiation in Late 2025 Pre-Clinical Data for Oral OXM in Obesity and Oral GLP-2 in Short Bowel Syndrome in Collaboration with OPKO Presented at ENDO2025 and ESPEN JERUSALEM, Nov. 14, 2025 (GLOBE NEWSWIRE) — Entera Bio Ltd. (NASDAQ: ENTX) (“Entera” or the “Company”), a leader in the development of oral peptide and protein replacement therapies, today reported financial results and key business updates for the quarter ended September 30, 2025. “Our achievements this quarter are testament to Entera’s leadership...

FREDERICK, Md., Nov. 14, 2025 (GLOBE NEWSWIRE) — TOMI Environmental Solutions, Inc. (NASDAQ: TOMZ), a global provider of disinfection and decontamination essentials through its premier Binary Ionization Technology® (BIT™) platform, today announced financial results for the quarter ended September 30, 2025, and provided an update on strategic initiatives designed to drive long-term growth. Q3 2025 Highlights:Revenue Growth: Revenues of $2.0 million reflecting a 95% sequential increase over Q2 2025, driven primarily by higher equipment purchases and continued strength in our recurring BIT™ Solution sales. Strong Gross Margins: Gross profit margin remained healthy at 61% in Q3, underscoring the efficiency of operations and the value of the Company’s technology. Operational Efficiencies: Reduced selling, research, and...

MIDLAND, Pa., Nov. 14, 2025 (GLOBE NEWSWIRE) — Mawson Infrastructure Group Inc. (NASDAQ: MIGI) (“Mawson” or the “Company”), a U.S.-based technology company that designs, builds, and operates next-generation digital infrastructure platforms providing services to the artificial intelligence (AI), high-performance computing (HPC), and digital assets (including Bitcoin mining), and other intensive compute applications market sectors, announced today its financial and operational results for the three and nine months ended September 30, 2025. Kaliste Saloom, Interim CEO of Mawson, said, “Our third quarter results clearly demonstrate Mawson’s ongoing commitment to growth and our resilience. With significant improvements in revenue, gross profit, and net income, we are making real progress toward sustained profitability. The successful...

DALLAS, Nov. 14, 2025 (GLOBE NEWSWIRE) — Strive, Inc. (Nasdaq: ASST) (“Strive” or the “Company”), the first Bitcoin treasury company amplified exclusively with perpetual preferred equity, today announced its financial results for the third quarter ended September 30, 2025. Third Quarter 2025 Highlights:Consummated the reverse acquisition of Asset Entities Inc. and concurrently raised $762.6 million through PIPE financing transaction and warrant exercises through September 30, 2025, with the opportunity to raise an additional $736.6 million through exercise of remaining warrants. Announced the entry into an agreement and plan of merger for the acquisition of Semler Scientific, Inc. (“Semler”) in an all-stock transaction that would result in Semler being a wholly owned subsidiary of Strive, subject to the satisfaction...

–   Company reports $14.3 million in revenue in Q3’25, consisting of $3.6 million in YCANTH® revenue and $10.7 million of license and collaboration revenue – – Reports positive feedback from the FDA and alignment regarding the study design of a Phase 3 program for VP-315 in basal cell carcinoma; Company presented new data on VP-315 at the recent Society for Immunotherapy of Cancer conference – – Received positive feedback from European Medicines Agency that supports a Marketing Authorization Application filing for YCANTH for molluscum without need for additional Phase 3 studies – – Received $10 million cash milestone payment for approval of YCANTH for molluscum in Japan – – Conference call scheduled for Monday, November 17, 2025, at 8:30 am ET – WEST CHESTER, Pa., Nov. 14, 2025 (GLOBE NEWSWIRE) — Verrica Pharmaceuticals Inc. (“Verrica”)...

Third Quarter Net Sales and Adjusted EBITDA Exceeded Guidance Driven by 44% OEM GrowthGross Margin Expanded 710 Basis Points Year-over-YearRecent Public Offerings and Debt Restructuring Significantly Improve Financial PositionGuides to Fourth Quarter Net Sales of Approximately $13.0 Million Third Quarter 2025 Financial Highlights (All comparisons made are against the prior-year period)Net sales were $16.0 million, compared to $12.7 million, up 25.5%. OEM net sales were $10.7 million, compared to $7.4 million, up 44.3% Gross Margin was 29.7%, compared to 22.6%, up 710 basis points. Net Loss was $(11.1) million, compared to $(6.8) million. Adjusted EBITDA was $(2.1) million, compared to $(5.5) million.RENO, Nev., Nov. 14, 2025 (GLOBE NEWSWIRE) — Dragonfly Energy Holdings Corp. (“Dragonfly Energy” or the “Company”) (Nasdaq: DFLI),...